LONDON, June 28, 2017 /PRNewswire/ -- SummaryAccording to the recently published report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017'; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.Download the full report: https://www.reportbuyer.com/product/4959901/Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.The report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects- The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type- The report summarizes all the dormant and discontinued pipeline projects- The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeuticsReasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)- Identify the use of drugs for target identification and drug repurposing- Identify potential new clients or partners in the target demographic- Develop strategic initiatives by understanding the focus areas of leading companies- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics- Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscapeDownload the full report: https://www.reportbuyer.com/product/4959901/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com
For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/integrin-alpha-7-itga7---pipeline-review-h1-2017-300481154.html
SOURCE ReportBuyer